A Phase 2 interventional study of Tirzepatide and Placebo in Idiopathic Intracranial Hypertension (IIH), Pseudotumor Cerebri and Papilledema, sponsored by Brigham and Women's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pseudotumor Cerebri with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Pseudotumor Cerebri · United States.
Among the 17 studies in Pseudotumor Cerebri with a site in United States, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2027, is the only one in phase 2, and was the 17th registered.
54 studies on the registry are indexed under Pseudotumor Cerebri; 23 are open to participants now.
Browse Pseudotumor Cerebri studies →3 of the 17 studies in Pseudotumor Cerebri with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18–60
Thomas Jefferson University · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Pseudotumor Cerebri studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; none take children under 18; 3 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 60 across 36 interventional studies indexed under Pseudotumor Cerebri.
Median enrollment 50 across the 12 interventional studies, 18 across the 5 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 17 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 1 study filed under Pseudotumor Cerebri — fewer than ten, so there is no comparison to draw.
1 of the studies in Pseudotumor Cerebri with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07191873Duke UniversityTirzepatide in Idiopathic Intracranial Hypertension Trial | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Pseudotumor Cerebri with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if tirzepatide, a dual GIP/GLP-1 receptor agonist, helps to treat idiopathic intracranial hypertension (IIH) when added to acetazolamide, which is the standard medical therapy for IIH. The main questions it aims to answer are:
Investigators will compare tirzepatide to a placebo/sham injection in patients who are treated with a predefined dosing schedule of acetazolamide that adjusts based upon the response of papilledema and other IIH symptoms such as headache.
In addition to receiving treatment with acetazolamide, participants will:
Background. Acetazolamide is the current standard medical therapy for IIH and acts through inhibiting CSF production by the choroid plexus epithelium. The IIH Treatment Trial showed that acetazolamide improves visual field mean deviation, papilledema, and weight loss versus placebo, but the absolute effects were modest, headache was not significantly improved, and tolerability of acetazolamide remains a limitation. Tirzepatide and other GLP-1 agonists have potential benefit in IIH since they are effective for weight loss, and IIH can be put into remission with roughly 25% weight loss. Direct lowering of ICP by a mechanism similar to acetazolamide was also demonstrated for exenatide, another GLP-1 agonist. It is unclear if this ability extends to other members of the GLP-1 agonist class, but it is an appealing possibility.
Design. This is a single-center, randomized, double-masked, placebo-controlled, parallel-group phase 2 trial, reported per CONSORT 2025. Randomization is 1:1, administered by the BWH Research Pharmacy, stratified by (a) papilledema grade/visual loss severity and (b) BMI category, using permuted blocks of varying size. Participants, treating clinicians, outcome assessors, and analysts are masked; only unblinded pharmacy staff know allocation.
Intervention. All participants receive extended-release acetazolamide starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), and up-titrated to a maximum of 4 g/day. Acetazolamide dose is titrated at study visits by predefined rules based on perimetric mean deviation, papilledema (Frisén grade, OCT pRNFL), and a 14-day headache score. Participants also self-inject weekly tirzepatide or matching placebo starting at 2.5 mg one week after acetazolamide initiation, increasing monthly (5, 7.5, 10, 12.5 mg) to a maximum of 15 mg weekly as tolerated. All participants receive standardized nutrition and exercise guidance.
Visits. Screening/baseline, then visits at months 1, 2, 3, 5, 7, 10, and 12, with telephone or video contacts at months 4, 6, 8, 9, and 11. Assessments include visual acuity, automated perimetry (HVF 24-2 SITA Standard), OCT (Cirrus; Spectralis at baseline and 12 months), OCT angiography, fundus photography, weight and abdominal circumference, headache/quality-of-life/sleep questionnaires, lumbar puncture at month 12, and DXA and MRI at baseline and 12 months. After month 12, participants are followed open-label through month 24.
Primary endpoint is mean daily acetazolamide dose at the 12-month visit in participants with baseline BMI ≥27.0.
Statistics. Sample size is based on detecting a 375 mg/day difference (SD 450 mg, two-sided alpha 0.05, 80% power), requiring about 47 completers, inflated for 30% loss to follow-up. The primary analysis is a mixed linear model adjusted for stratification factors with a random site intercept. One interim analysis is planned using a group-sequential design (Lan-DeMets O'Brien-Fleming alpha spending) with a one-time promising-zone sample size adaptation.
Safety. Adverse events are graded with CTCAE v6.0. Medical and statistical monitors review safety data. Predefined criteria govern withdrawal and treatment failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
IIH with papilledema, adapted from the 2013 diagnostic criteria and the modified Dandy criteria used in the IIH Treatment Trial:
(i) Papilledema confirmed by a neuro-ophthalmologist (ii) Lumbar puncture opening pressure >25 cm CSF within 6 weeks of enrollment with normal CSF constituents; if opening pressure is 20-25 cm CSF, at least one of: venous pulsatile tinnitus, sixth cranial nerve palsy, Frisén grade ≥2 papilledema with pseudopapilledema excluded in at least one eye, or bilateral transverse venous sinus stenosis (iii) MRI and MRV of the brain showing no cause of secondary intracranial hypertension (e.g., tumor, hydrocephalus, venous sinus thrombosis)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous tirzepatide starting 2.5 mg and escalated monthly as tolerated to a maximum of 15 mg weekly, for 12 months; standard nutrition and exercise counseling.
Drug: Tirzepatide · Drug: Acetazolamide
Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous placebo injection on the same escalation schedule, for 12 months; standard nutrition and exercise counseling.
Drug: Placebo · Drug: Acetazolamide
Weekly subcutaneous self-injection via autoinjector, starting 1 week after acetazolamide initiation at 2.5 mg and increasing every month to 5, 7.5, 10, 12.5, and 15 mg weekly as tolerated. Down-titration by one step and discontinuation at 2.5 mg are allowed for intolerance. Other names: Mounjaro; Zepbound.
Weekly subcutaneous placebo injection matched to tirzepatide in appearance and delivery device, with the same dose-escalation schedule.
Extended-release capsules, starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), titrated at study visits in 500 mg steps by predefined rules, maximum 4 g/day.
Mean daily acetazolamide dose at 12 months
Mean daily acetazolamide dose (mg/day) at 12 months in participants with baseline BMI ≥27.0
Time frame: 12 months
Cumulative acetazolamide dose
Area under the curve (cumulative dose) of acetazolamide over the study
Time frame: Baseline to 12 months
Between-group comparison of acetazolamide dose at each study visit
Time frame: Months 1, 2, 3, 5, 7, 10, 12
Time to initiation of acetazolamide down-titration (days)
Time frame: Baseline to 12 months
Remission rate (off acetazolamide)
Proportion of participants off acetazolamide (remission) at 12 months and sustained through the subsequent visit.
Time frame: Baseline to 15 months
Best-corrected visual acuity
Change in best-corrected visual acuity (ETDRS, logMAR) in each eye. ≥0.3 logMAR (15-letter) change considered significant difference.
Time frame: Baseline to 12 months
Visual field perimetric mean deviation
Change in perimetric mean deviation (HVF 24-2 SITA Standard)
Time frame: Baseline to 12 months
Papilledema Frisén grade
Change in Frisén papilledema grade from fundus photographs (masked grader), and mean grade at each visit.
Time frame: Baseline to 12 months
Peripapillary retinal nerve fiber layer (pRNFL) thickness
Change in mean pRNFL thickness (microns) measured using optical coherence tomography (Cirrus device)
Time frame: Baseline to 12 months
Combined ganglion cell-inner plexiform layer (GCIPL) thickness
Change in macular ganglion cell-inner plexiform layer (GCIPL) thickness (Cirrus, microns) measured using optical coherence tomography.
Time frame: Baseline to 12 months
Peripapillary capillary density on optical coherence tomography angiography (OCT-A)
Change in peripapillary capillary density on OCT-A (Cirrus)
Time frame: Baseline to 12 months
Change in lumbar puncture opening pressure
LP opening pressure measured in cm cerebrospinal fluid (CSF)
Time frame: Baseline to 12 months
Proportion of patients with new spontaneous cerebrospinal fluid leak
Time frame: Baseline to 12 months
Composite National Eye Institute Visual Function Questionnaire 25 (VFQ-25) plus 10-item neuro-ophthalmology supplement score
Measure of vision-related quality of life and self-reported health status on a scale of 0-100. A higher score indicates better quality of life.
Time frame: Baseline to 12 months
Migraine disability assessment test (MIDAS)
5-item questionnaire measuring headache-related disability over a 3 month period. Score is the sum of days from individual questions. Higher scores signify greater headache disability. Score ranges from 0-270.
Time frame: Baseline, months 3, 7, 12
Headache impact test (HIT-6)
6 item questionnaire measuring how headaches affect daily life, work and social activities. Score ranges from 36 (no impact) to 78 (severe impact).
Time frame: Baseline, months 3, 7, 12
14-day headache score
Count of days with headache lasting more than 4 hours or requiring acute medical treatment within the prior 14 days.
Time frame: Baseline, months 1-12
Time to symptom control
Time (days) to symptom control (\<4 symptom days/month of headache, pulsatile tinnitus, or transient visual obscuration).
Time frame: Baseline to 12 months
Proportion with symptom control
Proportion of patients with symptom control (\<4 days/month of headache, pulsatile tinnitus, or transient visual obscuration)
Time frame: Baseline to 12 months
Brain fog scale score
23 item questionnaire with total score ranging from 0 to 92. Higher scores indicate increased levels of brain fog.
Time frame: Baseline to months 3, 7, 12
Percent reduction in body weight
Percent reduction in body weight. Positive value represents weight loss and negative value represents weight gain.
Time frame: Baseline to 12 months
Body Mass Index (BMI)
Change in BMI measured in kg/m2. Positive value represents an increase in BMI and a negative value represents a decrease in BMI.
Time frame: Baseline to 12 months
Abdominal circumference
Change in abdominal circumference (cm). Positive value represents increase in circumference, and negative value represents a decrease in circumference.
Time frame: Baseline to 12 months
Body fat mass
Change in dual-energy x-ray absorptiometry (DXA) measure of body fat mass (kg). Positive value represents an increase in body fat mass, and negative value represents a reduction in body fat mass.
Time frame: Baseline to 12 months
Percent body fat
Change in dual-energy x-ray absorptiometry (DXA) measures of percent body fat. Positive value represents an increase in percent body fat, and negative value represents a reduction in percent body fat.
Time frame: Baseline to 12 months.
Android/gynoid ratio
Dual-energy x-ray absorptiometry (DXA) measure of android/gynoid ratio change. A/G ratio is the percentage or mass of android (abdominal) fat divided by the gynoid (hip/thigh) fat. A higher ratio (\>1.0) indicates more weight is carried in the midsection. A lower ratio (\<1.0) indicates more weight is carried in the hips and thighs. Increase in A/G ratio indicates an increase in abdominal/visceral fat relative to hip/thigh fat, while a decrease in A/G ratio indicates a reduction in abdominal/visceral fat relative to hip/thigh fat.
Time frame: Baseline to 12 months
Bone mineral density
Change in dual-energy x-ray absorptiometry (DXA) measure of bone mineral density (g/cm2). Positive value represents an increase in bone mineral density, and negative value represents reduction in bone mineral density.
Time frame: Baseline and 12 months.
Structural magnetic resonance imaging (MRI) features of intracranial hypertension
Change in the number of structural MRI features of intracranial hypertension (partially empty sella, optic nerve sheath distention, posterior globe flattening, and presence of transverse venous sinus stenosis). Score ranges from -4 to 4. Negative score indicates resolution of findings, and a positive score indicates development of additional findings.
Time frame: Baseline to 12 months
Pituitary gland height
Maximum pituitary gland height (mm) measured orthogonal to the sellar floor on mid-sagittal T1 weighted MRI sequence.
Time frame: Baseline to 12 months
Optic nerve sheath diameter (mean)
Maximum diameter of the optic nerve sheath as measured on axial T2 weighted MRI within the orbit, averaged between right and left
Time frame: Baseline and 12 months
Combined conduit score (CCS)
Using 3D T1-weighted MRI and MR venogram time-of-flight sequences, each transverse-sigmoid sinus conduit (right and left) is evaluated between the torcula and distal sigmoid sinus. The degree of narrowing on each side is assigned a value: 0 - aplastic or flow gap; 1 - hypoplastic or narrowed to \<25% expected diameter; 2 - narrowed to 25-50% expected diameter; 3 - narrowed to 50-75% expected diameter; 4 - narrowed to 75-100% expected diameter). The CCS is the sum of the scores of the right and left side and ranges from 0 to 8. From Farb et al. 2003.
Time frame: Baseline to 12 months
Diffusion tensor imaging along the perivascular space (DTI-ALPS) index
Change in ALPS index. It is calculated as a ratio of water diffusivity values measured along different axes in specific white matter regions near the lateral ventricles to isolate perivascular diffusivity. ALPS indices are unitless. An increase in ALPS index represents an increase in extracellular/glymphatic fluid transit.
Time frame: Baseline to 12 months.
Epworth Sleepiness Scale (ESS)
Change in ESS. Score ranges from 0 to 24. Increase in ESS indicates worsened symptoms related to obstructive sleep apnea.
Time frame: Baseline to 12 months
STOP-Bang score (S-Snoring; T-Tired; O-Observed; P-Pressure; B-BMI; A-Age; N-Neck; G-Gender)
Change in STOP-Bang score. Score ranges from 0 to 8. Increase in STOP-Bang indicates worsened symptoms related to obstructive sleep apnea (OSA).
Time frame: Baseline to 12 months
Apnea-hypopnea index (AHI)
Change in apnea-hypopnea index (AHI) in patients with obstructive sleep apnea (OSA) who also complete a follow up sleep study at 12 months. AHI are the number of breathing disturbances/hour during sleep. An increase in AHI indicates worsening of sleep disorder breathing/OSA, while a decrease in AHI indicates improvement.
Time frame: Baseline to 12 months.
Adverse Events
Number of participants with adverse events (AE) (CTCAE v6.0)
Time frame: Baseline to 24 months
Serious Adverse Events
Number of participants with severe adverse events
Time frame: Baseline to 24 months
Treatment-related withdrawals
Number of participants with treatment-related withdrawals
Time frame: Baseline to 12 months
Treatment failures
Number of patients with treatment failures
Time frame: Baseline to 12 months
Plan to share: No — We did not seek MGB IRB approval for data sharing outside of Mass General Brigham.
Start is estimated for Jan 2027; primary completion for May 2030, 40 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
Brigham and Women's Hospital →